1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Phase 2: new trials by email Literature Review of Phase 2 trials Research Report on Phase 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) - Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Phase 1 / Phase 2 | Recruiting | enGene, Inc. | 350 | 2021-04-22 | 2026-08-07 |
| Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS Omacetaxine, Azacitidine - High Grade Myelodysplastic Syndromes | Phase 1 / Phase 2 | Active not recruiting | University of Colorado, Denver | 29 | 2018-09-17 | 2026-09-29 |
Carcinoma in Situ (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Urinary Bladder Neoplasms (1)
University of Colorado, Denver (1) · enGene, Inc. (1)
United States (2) · Australia (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Christine Tosone, Ms, RAC (1) · Daniel Pollyea, MD (1)